What one share of Opus Genetics holds
Opus Genetics, Inc. (the “Company,” “Opus,” “we,” “us,” or “our”) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent
Opus Genetics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.12 |
|---|---|
| Profit | −$1.29 |
| Cash and investments | $1.07 |
| Debt | $0.43 |
| Book value | −$0.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.00 | −$6.00 | — | — | — | $10.13 |
| 2010 | $0.00 | −$21.60 | — | — | — | $14.82 |
| 2011 | $0.00 | −$14.63 | — | — | — | $13.47 |
| 2012 | $0.00 | −$7.20 | — | — | — | $9.58 |
| 2013 | $0.00 | −$8.40 | — | — | — | $10.33 |
| 2014 | — | −$13.20 | — | — | — | $17.89 |
| 2015 | — | −$9.46 | — | — | — | $11.41 |
| 2016 | — | −$5.14 | — | — | — | $8.62 |
| 2017 | — | −$11.08 | — | — | — | $6.34 |
| 2018 | — | −$5.25 | — | — | — | −$0.54 |
| 2019 | $1.05 | −$2.17 | $0.01 | −$1.27 | — | −$2.65 |
| 2020 | $0.00 | −$5.28 | $0.00 | −$1.46 | — | — |
| 2021 | $0.04 | −$3.82 | — | — | — | $1.18 |
| 2022 | $1.93 | $0.87 | — | — | — | $2.22 |
| 2023 | $0.88 | −$0.46 | — | — | — | $2.08 |
| 2024 | $0.41 | −$2.15 | — | — | — | $0.21 |
| 2025 | $0.23 | −$0.80 | — | — | — | $0.22 |
Common questions about Opus Genetics
How much does one share of Opus Genetics earn?
Over the last 12 months, Opus Genetics lost $1.29 for each share on $0.12 of sales.
Does Opus Genetics pay a dividend?
Opus Genetics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Opus Genetics’s book value per share?
Opus Genetics’s book value is negative (−$0.16 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Opus Genetics have?
Each share of Opus Genetics has $1.07 of cash and investments and $0.43 of debt, as of June 30, 2026.
Has Opus Genetics bought back shares?
Opus Genetics’s share count rose about 12760% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.